VISEN Pharmaceuticals and MedSci Enter Strategic Collaboration to Accelerate Digital Transformation in Endocrine Therapeutics

On December 23, VISEN, a biopharmaceutical company focused on innovative drugs in the field of endocrinology, officially signed a strategic agreement with MedSci, a well-known professional medical platform in China. The two parties will leverage their respective resource and capability advantages to carry out comprehensive and in-depth cooperation in the fields of endocrinology and rare diseases, including the construction of an academic platform for endocrinology, the development of a digital ecosystem for doctors and patients, and a series of digital solutions such as digital disease management.

VISEN CEO Lu Anbang, Chief Marketing Officer Chen Jun, Vice President of Sales Pan Haifeng, Vice President of Corporate Communications Wu Yan, Senior Director of Marketing Gu Qing, and Director of Compliance and Legal Affairs Wang Chao, along with MedSci Chairman Zhang Fabao, Deputy General Manager Sun Chao, and Senior Director of Business Development Wu Qinghua, attended the on-site signing ceremony.

According to Lu Anbang, CEO of VISEN Pharmaceuticals, there is a significant unmet need in the field of pediatric endocrinology. VISEN remains firmly focused on adult endocrinology, pediatric endocrinology, and rare endocrine diseases, committed to providing first-in-class or best-in-class innovative drugs with high market urgency to enable target pediatric patients to grow up healthier. Among the three products in VISEN’s pipeline, the one used for treating pediatric growth hormone deficiencyLonapegsomatropinNow in Phase III clinical trials, the product is expected to submit a marketing authorization application to the National Medical Products Administration (NMPA) in 2022. It has the potential to become China’s first long-acting growth hormone that exerts its therapeutic effect by releasing unmodified human growth hormone molecules. At this critical juncture of accelerating R&D and product launch, entering into a strategic partnership with MedSci will enable more efficient and precise academic promotion, thereby enhancing corporate momentum.

Zhang Fabao, Chairman of MedSci, believes that as innovative pharmaceutical companies evolve from biotech to biopharma, and further toward big pharma, they require not only R&D innovation but also commercial innovation. As one of the earliest enterprises in China dedicated to digital innovation in medicine and commerce, MedSci has engaged in multi-dimensional, in-depth collaborations with over 100 pharmaceutical companies both domestically and internationally. Leveraging its extensive physician platform, MedSci provides innovative drug companies with medical affairs services, digital academic dissemination, and digital clinical research solutions. Centered on evidence-based medicine, it creates a closed loop encompassing the generation, interpretation, and dissemination of evidence for innovative drugs. Before and after the market launch of innovative drugs, it is essential to continuously explore their connotations and value, and to convey the core value propositions of these drugs to target physicians and patients through digital means, enabling broader and faster familiarity with innovative therapies among the target healthcare community and patient population.

Currently, both parties have engaged in in-depth collaboration in areas such as medical strategy, medical services, and expert-led scientific research and academic support. Following the product launch, they will further strengthen their partnership with more close and long-term cooperation in online physician education, patient education, and digital marketing.

Following the signing ceremony, Chen Jun, Chief Marketing Officer of VISEN Pharmaceuticals, engaged in an in-depth dialogue with Zhang Fabao, Chairman of MedSci. Chen Jun stated that amidst the unprecedentedly fervent market environment for innovative drug development in oncology and immunology, VISEN Pharmaceuticals has rooted itself in the relatively less crowded endocrinology sector, driven by the substantial market demand for endocrine disorders. The company is committed to providing first-in-class or best-in-class products and treatment solutions for endocrine diseases, thereby improving the quality of life for patients with rare diseases in China. Addressing the impact of the digital wave on the pharmaceutical industry, Zhang Fabao, Chairman of MedSci, remarked that digitalization serves as the foundational infrastructure for the future of the pharmaceutical sector, permeating every aspect of the industry chain. In the realm of pharmaceutical communication, he emphasized that academic rigor is the prerequisite for digitalization; dissemination must be grounded in evidence-based medicine. Only then can digital marketing achieve greater precision, speed, authenticity, and value.

This strategic partnership between VISEN and MedSci will maximize the synergistic advantages of both parties, unleash digital momentum, and jointly drive comprehensive corporate development from R&D innovation to commercial innovation. Together, they will work to make innovative medicines accessible to target patients earlier and faster, contributing to the advancement of the Healthy China strategy.

VISEN is an innovative biopharmaceutical company focused on endocrinology-related therapeutic areas. Prioritizing patient needs, VISEN is dedicated to providing first-in-class or best-in-class products and treatment solutions for endocrine disorders. Its therapeutic areas include adult endocrinology, pediatric endocrinology, and rare endocrine diseases. VISEN continues to attract senior professionals with international backgrounds and leverage cutting-edge global technologies and resources. With a deep commitment to the Chinese market, the company has established offices in Shanghai, Beijing, Hong Kong, and Taipei, and set up a Greater China R&D and manufacturing base in Suzhou. This enables VISEN to implement a full-chain layout spanning R&D, production, and sales in the field of innovative endocrine medicines, ensuring that more Chinese patients with endocrine disorders can benefit earlier from advanced and reliable global treatment solutions.

MedSci is a comprehensive internet platform for physicians that leverages big data and artificial intelligence to connect doctors, patients, pharmaceutical and medical device companies, and other stakeholders. It provides precise digital medical communication solutions, empowers the healthcare ecosystem, improves the quality of care, and jointly creates a better and healthier life.

MedSci’s core offerings include digital medical communication and digital clinical research, spanning categories such as clinical research, physicians’ professional development, multi-channel academic dissemination, and smart healthcare. In the realm of digital clinical research, it provides comprehensive solutions that leverage digital technologies to reduce costs and enhance quality. In digital medical communication, it delivers specialized digital medical content alongside precise, integrated communication strategies, accurately conveying the latest disease knowledge and information on pharmaceuticals and medical devices to target physicians and patients, thereby benefiting a broader patient population more quickly and at an earlier stage.

MedSci has established offices in Shanghai, Beijing, Hefei, Hangzhou, and Los Angeles to better serve and support the development of China’s innovative pharmaceutical industry.